<unk> , sold under the brand name Qtern, is a fixed-dose combination anti-diabetic medication used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It is a combination of dapagliflozin and<unk> . It is taken by mouth. The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).<unk>  was approved for medical use in the European Union in July 2016, and in the United States in February 2017.
Dapagliflozin/saxagliptin
Canagliflozin/metformin
Empagliflozin/linagliptin
Empagliflozin/metformin
Insulin degludec/liraglutide
Pioglitazone/metformin
Pioglitazone/glimepiride
Dapagliflozin/metformin